{"id":909174,"date":"2025-11-12T16:34:52","date_gmt":"2025-11-12T21:34:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/innovate-corp-announces-third-quarter-2025-results\/"},"modified":"2025-11-12T16:34:52","modified_gmt":"2025-11-12T21:34:52","slug":"innovate-corp-announces-third-quarter-2025-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/innovate-corp-announces-third-quarter-2025-results\/","title":{"rendered":"INNOVATE Corp. Announces Third Quarter 2025 Results"},"content":{"rendered":"
\n

\n – Infrastructure: DBM Global delivers robust revenue growth, reinforcing market leadership –<\/em>
\n
\n – Life Sciences: MediBeacon received regulatory approval to sell the Transdermal GFR System in China<\/em>
\n –<\/em>
\n
\n – Spectrum: New network launches underway; F<\/em>
\n ourth quarter advertising sales showing early signs of recovery<\/em>
\n – <\/em>\n <\/p>\n

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) — INNOVATE Corp. (\u201cINNOVATE\u201d or the \u201cCompany\u201d) (NYSE: VATE) announced today its consolidated results for the third quarter.<\/p>\n

\u00a0Financial Summary<\/strong><\/p>\n\n\n\n\n\n\n\n
(in millions, except per share amounts)<\/td>\n\n Three Months Ended September 30,<\/strong>\n <\/td>\n\u00a0<\/td>\n\n Nine Months Ended September 30,<\/strong>
\n
\n
\n <\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\n 2025<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2024<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n Increase \/ (Decrease)<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2025<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2024<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n Increase \/ (Decrease)<\/strong>
\n
\n
\n <\/strong>\n <\/td>\n<\/tr>\n
Revenue<\/td>\n$<\/td>\n347.1<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n242.2<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n43.3<\/td>\n%<\/td>\n\u00a0<\/td>\n$<\/td>\n863.3<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n870.5<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(0.8<\/td>\n)%<\/td>\n<\/tr>\n
Net loss attributable to common stockholders and participating preferred stockholders<\/td>\n$<\/td>\n(9.4<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(15.3<\/td>\n)<\/td>\n\u00a0<\/td>\n38.6<\/td>\n%<\/td>\n\u00a0<\/td>\n$<\/td>\n(56.2<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(18.9<\/td>\n)<\/td>\n\u00a0<\/td>\n(197.4<\/td>\n)%<\/td>\n<\/tr>\n
Basic and Diluted loss per share attributable to common stockholders<\/td>\n$<\/td>\n(0.71<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(1.18<\/td>\n)<\/td>\n\u00a0<\/td>\n39.8<\/td>\n%<\/td>\n\u00a0<\/td>\n$<\/td>\n(4.27<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(1.69<\/td>\n)<\/td>\n\u00a0<\/td>\n(152.7<\/td>\n)%<\/td>\n<\/tr>\n
Total Adjusted EBITDA(<\/sup>1<\/sup>)<\/sup><\/td>\n$<\/td>\n19.8<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n16.8<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n17.9<\/td>\n%<\/td>\n\u00a0<\/td>\n$<\/td>\n42.7<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n56.3<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(24.2<\/td>\n)%<\/td>\n<\/tr>\n<\/table>\n

(1) Reconciliation of GAAP to Non-GAAP measures follows<\/p>\n

\n Commentary<\/strong>\n <\/p>\n

“INNOVATE built on the momentum from the first half of the year, delivering steady execution and progress across all of our operating segments,” said Avie Glazer, Chairman of INNOVATE. “We remain focused on advancing our strategic priorities, strengthening our balance sheet, and position each of our businesses for long-term value creation. In Infrastructure, adjusted backlog grew to $1.6\u00a0billion this quarter, supported by a growing pipeline of high-quality projects and disciplined operational execution. Turning to Life Sciences, we continue to see positive momentum. Of note, MediBeacon received regulatory approval to sell the Transdermal GFR System in China. Additionally, R2 remains on a strong growth trajectory and has continued commercial applications. Lastly, despite the headwinds in the over-the-air broadcast marketplace with Spectrum, we are excited about several new network launches and emerging opportunities in datacasting.”<\/p>\n

“We’re making solid progress across INNOVATE as we stay focused on delivering value to our shareholders,” said Paul Voigt, Interim CEO of INNOVATE. “DBM Global’s strong year-to-date revenue and robust backlog showcases their disciplined execution and ability to secure complex projects. MediBeacon’s regulatory approval to sell their product in China is a major milestone that broadens the scope of our addressable market. Hitting these milestones, coupled with our disciplined cost management, places INNOVATE in a strong position to execute on our strategy.”<\/p>\n

\n Third Quarter 2025 and Recent Highlights<\/strong>\n <\/p>\n